← Back to Screener
Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Price$13.47
Favorite Metrics
Price vs S&P 500 (26W)5.14%
Price vs S&P 500 (4W)1.32%
Market Capitalization$524.38M
All Metrics
Book Value / Share (Quarterly)$6.99
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.49
Price vs S&P 500 (YTD)14.23%
EPS (TTM)$-2.20
10-Day Avg Trading Volume0.33M
EPS Excl Extra (TTM)$-2.20
EPS (Annual)$-2.17
ROI (Annual)-22.98%
Cash / Share (Quarterly)$7.04
ROA (Last FY)-21.68%
EBITD / Share (TTM)$-2.56
ROE (5Y Avg)-26.99%
Cash Flow / Share (Annual)$-1.49
P/B Ratio2.01x
P/B Ratio (Quarterly)1.60x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-112.73x
ROA (TTM)-28.08%
EPS Incl Extra (Annual)$-2.17
Current Ratio (Annual)27.50x
Quick Ratio (Quarterly)26.98x
3-Month Avg Trading Volume0.29M
52-Week Price Return208.90%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)10.49x
Asset Turnover (Annual)0.38x
52-Week High$16.33
EPS Excl Extra (Annual)$-2.17
26-Week Price Return13.89%
Quick Ratio (Annual)26.98x
13-Week Price Return15.05%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)27.50x
Enterprise Value$448.778
Revenue / Employee (Annual)$0
Pretax Margin (Annual)46.34%
Cash / Share (Annual)$7.04
3-Month Return Std Dev61.93%
Net Income / Employee (TTM)$-1
ROE (Last FY)-22.98%
EPS Basic Excl Extra (Annual)$-2.17
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.20
ROI (TTM)-29.75%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)173.81%
Year-to-Date Return18.37%
5-Day Price Return6.03%
EPS Normalized (Annual)$-2.17
ROA (5Y Avg)-22.63%
Net Profit Margin (Annual)45.44%
Month-to-Date Return3.60%
EBITD / Share (Annual)$-2.45
Operating Margin (Annual)32.15%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-25.17%
EPS Basic Excl Extra (TTM)$-2.20
P/B Ratio (Annual)1.60x
Book Value / Share (Annual)$6.99
Price vs S&P 500 (13W)12.19%
Beta-0.55x
P/FCF (Annual)27.69x
Revenue / Share (TTM)$0.00
ROE (TTM)-29.75%
52-Week Low$3.35
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.38
4.31
4.31
4.31
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CTNMContineum Therapeutics, Inc. Class A Common Stock | — | — | — | — | $13.47 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Contineum Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapies for serious diseases with high unmet need. The company's pipeline includes PIPE-791, a brain-penetrant LPA1 receptor inhibitor in development for idiopathic pulmonary fibrosis, and PIPE-307, a muscarinic M1 receptor inhibitor for depression and relapsing-remitting multiple sclerosis.